格隆汇1月19日丨海利得(002206.SZ)在投资者互动平台表示，目前公司LCP相关产品尚未应用在脑机接 口业务。 ...

Core Viewpoint - The company, Zhijiang Biology, confirmed that it does not currently engage in brain-computer interface (BCI) related business activities [1] Group 1: Company Overview - Zhijiang Biology's main business focuses on molecular diagnostic reagents and equipment [1] - The applications of the company's products include medical clinical diagnosis, public health safety, entry-exit inspection and quarantine, and food safety [1] - The company has not expanded into the brain-computer interface sector [1]

Market Overview - On the 19th, the Shanghai Composite Index experienced fluctuations and rose, while the ChiNext Index saw a decline of over 1% at one point; more than 3,500 stocks in the A-share market were in the green [1] - By the close, the Shanghai Composite Index increased by 0.29% to 4,114 points, the Shenzhen Component Index slightly rose by 0.09%, and the ChiNext Index fell by 0.7%; the total trading volume in the Shanghai, Shenzhen, and North markets was approximately 2.73 trillion yuan [1] Sector Performance - Sectors such as semiconductors, banking, and insurance saw declines, while military industry, tourism, steel, coal, non-ferrous metals, and food and beverage sectors experienced gains [1] - Active themes included ultra-high voltage, military trade concepts, Hainan free trade, and wind power [1] Investment Sentiment - Huatai Securities noted that while the market continued to rise last week, investor sentiment declined due to events such as the increase in financing margin ratios and the pullback of themes like commercial aerospace; the current A-share risk premium has dropped to the lower end of the range [1] - Historically, further downward breakthroughs (indicating improved risk appetite) require fundamental support or strong incremental capital, both of which currently have low visibility; however, the current policy direction is positive, the inherent stability of the capital market has increased, and investor sentiment remains strong [1] Short-term Market Outlook - The market is expected to enter a short-term consolidation phase, with structural differentiation beginning to emerge; both thematic and cyclical investments have room for development [1] - For thematic investments, potential expansion directions include domestic computing power, humanoid robots, brain-computer interfaces, and AI applications; for cyclical investments, continued focus on the new energy chain with dual supply and demand improvements, storage, certain chemicals, consumer goods, and construction machinery is recommended [1]

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.29% and the ChiNext Index falling by 0.7% [2] - Over 3,500 stocks in the market experienced gains, while the total trading volume in the Shanghai and Shenzhen markets was 2.71 trillion yuan, a decrease of 317.9 billion yuan from the previous trading day [2] Sector Performance - Leading sectors included electric grid equipment, robotics, tourism and hotels, and precious metals, while the CPO concept faced declines [2] - The average stock price of the entire A-share market continued to rise, reaching the high point of the previous week [5] Fund Flow and ETF Activity - There was a notable reduction in heavy selling pressure from large funds in several major ETFs, indicating a potential stabilization in the market [7] - The trading volume of the Huatai-PB CSI 300 ETF was 13.793 billion yuan, showing a significant decrease in selling activity compared to previous days [7] Market Sentiment and Stock Performance - The number of stocks hitting the daily limit down decreased to 30, down from 72 and 61 in the previous two trading days, indicating a potential recovery in market sentiment [15] - Stocks such as Jin Feng Technology and Yan Shan Technology saw significant trading activity, with Jin Feng Technology recovering to a closing gain of 2.44% [13][12] Institutional Insights - Citic Securities noted that the recent market cooling is a strategic move to manage the bull market's pace, suggesting that the overall market sentiment remains positive despite short-term adjustments [17] - Guosheng Securities indicated that the market's short-term adjustment may be nearing completion, with a likelihood of continued upward movement in the near future [18]

智通财经APP获悉，华福证券发布研报称，近期，超声脑机接口公司MergeLabs完成约2.5亿美元种子轮 融资，此次融资由OpenAI领投。不同于主流脑机接口技术，MergeLabs聚焦超声为核心的非侵入或极 低侵入式路线。MergeLabs的超声路线试图在非侵入式(安全但分辨率有限)与植入式(信号清晰但有外科 风险、伦理监管问题)之间寻找平衡，其超声的深部穿透能力与"软接口"设想具备独特潜力。但该技术 目前仍处于实验室研究阶段。 当前脑机接口主要分为非侵入式、植入式及低侵入式三类路径，MergeLabs的超声路线试图在非侵入式 (安全但分辨率有限)与植入式(信号清晰但有外科风险、伦理监管问题)之间寻找平衡，其超声的深部穿 透能力与"软接口"设想具备独特潜力。但该技术目前仍处于实验室研究阶段，面临分子信号稳定性、超 声空间分辨率与安全窗口、低信噪比下神经状态反推等多重未解决的难题，复杂性不亚于植入式系统。 "十五五"重点赛道，脑机接口市场规模有望快速增长 根据Precedence research，2024年全球脑机接口市场规模约为26.2亿美元，预计2025年将达到29.4亿美 元，到2034年有望增长至1 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Group 1 - The A-share market experienced fluctuations on January 19, with the medical device ETF (562600) declining by 0.54% in the afternoon session [1] - Notable stock performances included Hualan Biological Engineering rising by 7.29%, Yirui Technology by 2.34%, Dian Diagnostics by 1.94%, and Aidi Te by 1.82% [1] - The medical device ETF (562600) has seen significant capital inflow, with a net inflow of 125 million yuan over the past five days and 256 million yuan over the past ten days [1] Group 2 - The medical device sector is expected to benefit from opportunities in overseas expansion, brain-computer interfaces, and AI healthcare by 2026 [2] - The overseas business revenue of the second-largest weight stock in the medical device ETF, United Imaging Healthcare, grew by 41.97% year-on-year in the first three quarters of 2025, becoming a significant source of revenue for the company [1][2] - The brain-computer interface market is at a critical turning point, with demand expected to be released, supported by China's 14th Five-Year Plan [2] - AI applications in healthcare are gradually being implemented, with Ant Group's AI health manager AQ reaching over 30 million monthly active users by January 2026 [2] - The medical device ETF (562600) tracks the CSI All-Share Medical Device Index, with a 23.8% allocation to brain-computer interfaces, the highest among similar ETFs, effectively capturing growth opportunities in niche markets [2]

智通财经APP获悉，华金证券发布研报称，据中研普华产业研究院预测，2022年中国脑机接口市场规模 约为10亿元人民币，年均复合增长率约为21%，市场发展潜力巨大。近期，脑机接口相关政策密集落 地，从聚焦技术路径来看，非侵入式技术以其"安全性高、成本低、易于普及"的特性，迅速从实验室走 向市场，推动医疗康复与消费场景的逐步落地，侵入式/半侵入式技术则凭借高精度信号采集的优势， 深耕高价值医疗应用，已在脊髓损伤、脑卒中等患者中实现初步运动功能重建，临床进展逐步推进。 华金证券主要观点如下： 脑机接口产业快速发展，国产厂商加速布局 据中研普华产业研究院预测，2022年中国脑机接口市场规模约为10亿元人民币，年均复合增长率约为 21%，市场发展潜力巨大。按照技术路径来看，非侵入式因技术难度相对较低，商业化较快，市场占比 最高，半侵入式市场占比居中，侵入式因技术难度较高，仍处于技术转临床阶段，市场占比相对较低。 政策不确定性风险、在研产品上市不确定性风险、研发进展不及预期风险等。 政策引领叠加技术突破，脑机接口商业化可期 脑机接口相关政策密集落地，七部门联合发布《关于推动脑机接口产业创新发展的实施意见》确立产业 战略蓝 ...

Core Insights - In 2025, China's fixed asset investment (excluding rural households) reached 48.5186 trillion yuan, a decrease of 3.8% from the previous year, with infrastructure investment down by 2.2% and real estate investment down by 17.2% [1][2] - Despite the overall decline in fixed asset investment, manufacturing investment grew by 0.6%, indicating a shift towards high-quality development in the economy [3][4] Investment Breakdown - Infrastructure investment saw a notable decline of 2.2%, while manufacturing investment increased by 0.6%, with specific sectors like railway, shipbuilding, and aerospace manufacturing experiencing a growth of 17.5% [1][2] - Real estate development investment fell by 17.2%, with new commercial housing sales area down by 8.7% and sales value down by 12.6% [1][2] - High-tech industries, particularly information services and aerospace equipment manufacturing, reported significant investment growth of 28.4% and 16.9% respectively [2][3] Policy Impact - The "Two New, Two Heavy" policy framework has played a crucial role in guiding investment trends, with infrastructure investment in key areas showing rapid growth [4][5] - The issuance of long-term special government bonds has facilitated increased investment in infrastructure, with pipeline transportation investment rising by 36.0% [4][5] - Equipment and tool procurement investment grew by 11.8%, contributing significantly to overall investment growth [5]

Core Viewpoint - The A-share market is experiencing fluctuations, with the CSI A500 index showing a slight increase while the ChiNext index is declining, reflecting mixed sector performances in the market [1] Group 1: Market Performance - As of 13:50, the CSI A500 index rose by 0.1%, while the ChiNext index fell by 0.9% [1] - Sectors such as precious metals, electric grid equipment, tourism, and controllable nuclear fusion are leading in gains, whereas AI applications, communication equipment, cloud computing, and gaming sectors are facing declines [1] Group 2: Economic Outlook - The National Bureau of Statistics indicates that by 2025, China's economy will exhibit a clear characteristic of "moving towards new," with R&D expenditure intensity reaching 2.8%, an increase of 0.11 percentage points from 2024, surpassing the OECD average for the first time [1] - Significant advancements in artificial intelligence, quantum technology, and brain-computer interfaces are reported, with a notable growth of 9.3% in the added value of large-scale digital product manufacturing compared to 2024 [1] Group 3: Index Composition - The CSI A500 index focuses on representative companies across various industries, covering 89 out of 93 sub-industries, with a higher weight on emerging sectors like information technology and healthcare [1] - The ChiNext index consists of 100 stocks from the ChiNext board, emphasizing high market capitalization and liquidity, with over 90% representation from strategic emerging industries [1] Group 4: Investment Products - The E Fund CSI A500 ETF (159361) and E Fund ChiNext ETF (159915) are among the largest in their categories, offering good liquidity and a low management fee of 0.15% per year, facilitating low-cost investment in quality leading companies in the A-share market [1]